- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- GT005
- Genetic
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 838
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Malignant Epithelial Neoplasms
- Interventions
- TCR-transduced T cells, CDX-1140, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- X-Linked Retinitis Pigmentosa
- Interventions
- rAAV2tYF-GRK1-hRPGRco, Control
- Biological · Drug
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 12 Years to 50 Years · Male only
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 15 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor, Ependymal Tumor
- Interventions
- C7R-GD2.CART cells (IV and ICV infusion)
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2041
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 13 Years to 55 Years
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Vestibular Schwannoma
- Interventions
- Not listed
- Lead sponsor
- Akouos, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2040
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- RGX-202
- Genetic
- Lead sponsor
- REGENXBIO Inc.
- Industry
- Eligibility
- 1 Year and older · Male only
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more
- Conditions
- Prostatic Neoplasms
- Interventions
- HSV-tk +Valacyclovir in Combination with Brachytherapy
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infection, Kaposi's Sarcoma
- Interventions
- Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
- Drug
- Lead sponsor
- National Human Genome Research Institute (NHGRI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Osteoarthritis, Knee
- Interventions
- XT-150
- Biological
- Lead sponsor
- Xalud Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Napa, California
- Conditions
- Metastatic Cancer
- Interventions
- in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HEPATITIS B CHRONIC
- Interventions
- PBGENE-HBV
- Biological
- Lead sponsor
- Precision BioSciences, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Wiskott-Aldrich Syndrome
- Interventions
- Retrovirus-mediated gene transfer
- Biological
- Lead sponsor
- David Williams
- Other
- Eligibility
- 3 Months to 35 Years · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma (Skin)
- Interventions
- gp100 antigen, sargramostim
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hemophilia B
- Interventions
- Not listed
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
- Conditions
- Duchene Muscular Dystrophy
- Interventions
- Not listed
- Lead sponsor
- ITF Therapeutics LLC
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more
- Conditions
- Carcinoma, Non-Small Cell Lung
- Interventions
- quaratusugene ozeplasmid, osimertinib, Platinum-Based Chemotherapy
- Biological · Drug
- Lead sponsor
- Genprex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Lone Tree, Colorado • Urbana, Illinois + 7 more
- Conditions
- Leber Hereditary Optic Neuropathy (LHON)
- Interventions
- NR082 Injection, Injection needle
- Drug · Device
- Lead sponsor
- Neurophth Therapeutics Inc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Aurora, Colorado • Philadelphia, Pennsylvania
- Conditions
- Metastatic Cancers
- Interventions
- Gene Modified T Cells
- Genetic
- Lead sponsor
- Roger Williams Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Hereditary Spastic Paraplegia Type 50
- Interventions
- MELPIDA
- Genetic
- Lead sponsor
- Elpida Therapeutics SPC
- Industry
- Eligibility
- 4 Months to 72 Months
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Interventions
- TN-401
- Genetic
- Lead sponsor
- Tenaya Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 7
- States / cities
- San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
- Conditions
- Tay Sachs Disease, Sandhoff Disease, Late Onset Tay Sachs Disease
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- Not listed
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Tampa, Florida • Minneapolis, Minnesota
- Conditions
- Breast Cancer, Cervical Cancer, Renal Cancer, Melanoma, Bladder Cancer
- Interventions
- Aldesleukin, Fludarabine, Cyclophosphamide, Anti-MAGE-A3 human leukocyte antigen serotype within HLA-A A serotype group (HLA-A* 01)-restricted T-cell receptor (TCR)
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- X-linked Retinoschisis
- Interventions
- rAAV2tYF-CB-hRS1
- Biological
- Lead sponsor
- Beacon Therapeutics
- Industry
- Eligibility
- 6 Years and older · Male only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 9
- States / cities
- San Francisco, California • Miami, Florida • Baltimore, Maryland + 6 more